Trends shaping the pharmaceutical industry in 2024
PharmaVoice
DECEMBER 18, 2023
Advancements in cloud and AI technology will transform clinical trial efficiency and engagement.
December, 2023
340 
Warning issued over fake pharmacy scam callers
The Pharmacist
DECEMBER 14, 2023
A scam alert has been issued over fraudsters phoning patients and pretending to be from a pharmacy. The scammers claim to be ringing to arrange delivery of medication, and ask patients to confirm their full name, date of birth, address and some banking details. According to Audit Yorkshire, which runs a counter fraud service for […] The post Warning issued over fake pharmacy scam callers appeared first on The Pharmacist.
Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
The Role of Pharmacists in HIV Care Continues to Expand
Pharmacy Times
DECEMBER 21, 2023
Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.
STAT+: UnitedHealth used secret rules to restrict rehab care for seriously ill Medicare Advantage patients
STAT
DECEMBER 28, 2023
Health insurance giant UnitedHealth Group used secret rules to restrict access to rehabilitation care requested by specific groups of seriously ill patients, including those who lived in nursing homes or suffered from cognitive impairment, according to internal documents obtained by STAT. The documents, which outline parameters for the clinicians who initially review referrals for rehab care, reveal that many patients enrolled in Medicare Advantage plans were routed for a quick denial based on c
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
As ALS research booms, one treatment center finds itself in the spotlight
BioPharma Dive
DECEMBER 20, 2023
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
PulmCrit: New ARDS guidelines reveal a shambolic state of affairs
EMCrit Project
DECEMBER 10, 2023
Within the past year, two major societies have released guidelines on ARDS: the ATS (American Thoracic Society) and the ESICM (European Society of Intensive Care Medicine). Don’t be fooled by their names – both of these organizations are fundamentally international in scope. Some authors on the ATS document were from Europe, and similarly some authors […] EMCrit Project by Josh Farkas.
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
More Trending
To fight rare diseases, win the data battle first
pharmaphorum
DECEMBER 18, 2023
To effectively combat rare diseases, it is essential to prioritise the collection and analysis of data. This article explores how pharmaceutical companies are leveraging AI and focusing on orphan drugs to tackle rare diseases.
NHSE plans ‘greater role’ for pharmacies in delivering seasonal jabs
The Pharmacist
DECEMBER 13, 2023
A new national vaccine strategy for England promises to ‘take vaccines into the heart of communities’ and overcome vaccine hesitancy. The plan, published today by NHS England (NHSE), designates community pharmacy as a ‘core’ setting for adult seasonal vaccinations, with local systems expected to ‘enable community pharmacy to play a greater role in seasonal vaccination […] The post NHSE plans ‘greater role’ for pharmacies in delivering seasonal jabs appeared first on The Pharmacist.
Quitting alcohol — or even drinking less — reduces risk of oral cavity and esophageal cancer, per new analysis
STAT
DECEMBER 27, 2023
Reducing or eliminating alcohol consumption reduces the risk of developing oral cavity and esophagus cancers, according to a special report from the International Agency for Research on Cancer. But more data are needed to conclude whether the same is true for several other cancer types, including colorectal, breast, and liver cancer. Even so, it is likely that reducing or ceasing to drink alcohol will lessen the risk of these cancers, said Farhad Islami, a cancer epidemiologist at the American C
‘No tolerance for failure’: An oral history of the first CRISPR medicine
BioPharma Dive
DECEMBER 10, 2023
A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. and U.K. This is the story of how it came to be.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
A Look Back: The Life Sciences Industry in 2023 and a View for 2024
PharmExec
DECEMBER 18, 2023
In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management with strategic investments will be vital.
Study suggests PBMs are gaming pharmacy system to overcharge for drugs
PharmaVoice
DECEMBER 15, 2023
Markups for generics can be as high as 7,000%, the researchers said.
BioNTech wins round in CureVac mRNA patent dispute
pharmaphorum
DECEMBER 20, 2023
Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation between CureVac and fellow German biotech BioNTech and its partner Pfizer, claiming infringement by their Comirnaty coronavirus shot.
Covid and flu hospital admissions twice as high in deprived areas, UKHSA warns
The Pharmacist
DECEMBER 11, 2023
A report by UK public health officials has highlighted stark inequalities in the complications of flu and Covid infection related to deprivation and ethnicity. Hospital admission rates for flu and Covid are more than two times higher for people living in more deprived areas, the analysis by the UK Health Security Agency (UKHSA) has concluded. […] The post Covid and flu hospital admissions twice as high in deprived areas, UKHSA warns appeared first on The Pharmacist.
STAT+: Complications spiked 25% in hospitals bought by private equity
STAT
DECEMBER 26, 2023
There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too. Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nur
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
BioPharma Dive
DECEMBER 8, 2023
In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.
FDA Grants Breakthrough Designation to Johnson & Johnson’s Novel Treatment for HR-NMIBC
PharmExec
DECEMBER 5, 2023
TAR-200 has a novel targeted releasing system for the treatment of patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer who are ineligible for bladder removal surgery.
ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease
European Pharmaceutical Review
DECEMBER 11, 2023
Results from MaaT Pharma’s Early Access Program (EAP) for its microbiome-based therapy MaaT013, have demonstrated positive overall response and overall survival rates in European patients with graft-versus-host disease (GvHD). The findings were presented at the 2023 American Society of Hematology (ASH) Annual Meeting. MaaT013 is an off-the-shelf, pooled-donor, enema Microbiome Ecosystem Therapy TM.
MSD, Moderna cancer vaccine aces melanoma study
pharmaphorum
DECEMBER 15, 2023
MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory filing.
Key Parkinson’s protein could offer new potential targets for treatment
Pharma Times
DECEMBER 20, 2023
The findings could lead to new treatments to target the mTOR and ease PD symptoms - News - PharmaTimes
We wish we’d written that: STAT staffers share their favorite stories of 2023
STAT
DECEMBER 29, 2023
It’s time to take stock of the year that was in health and science: the meteoric rise of weight loss drugs , the approval of the first CRISPR-based therapy , the continuing effects of abortion access restrictions after the Dobbs decision, and much more. Below is our annual list of stories that STAT staffers loved, and wish that they had written.
Tome Biosciences debuts with $213M and a new way to edit the genome
BioPharma Dive
DECEMBER 12, 2023
Based on the work of MIT scientists, the well-funded startup is developing ways to insert large sizes of genetic material anywhere in the genome without damaging or breaking DNA.
Finding that Spark
PharmExec
DECEMBER 13, 2023
Lisa Conte, founder, president, and CEO of Jaguar Health, discusses how a climb up Mount Kilimanjaro would vault her to her true career calling—and spark a decades-long quest to accelerate breakthroughs in plant-based pharmaceuticals and supportive care.
Understanding the evidence used in drug product withdrawals
European Pharmaceutical Review
DECEMBER 14, 2023
In the ever-evolving landscape of regulatory decisions, the quest for safeguarding public health remains paramount. Decisions to remove medicines from market are not taken lightly and are often based upon all evidence available to inform a benefit/risk balance. This evidence can come from a range of sources, such as randomised controlled trials (RCTs), observational studies, and spontaneous reporting.
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer
pharmaphorum
DECEMBER 7, 2023
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics which spun out of Pfizer in 2018.
PharmaKure and UiTM enter research partnership for Alzheimer’s disease
Pharma Times
DECEMBER 14, 2023
The collaboration aims to develop biomarker-based diagnostics for the condition - News - PharmaTimes
U.S. government spent more on health care in 2022 than six countries with universal health care combined
STAT
DECEMBER 19, 2023
American taxpayers footed the bill for at least $1.8 trillion in federal and state health care expenditures in 2022 — about 41% of the nearly $4.5 trillion in both public and private health care spending the U.S. recorded last year, according to the annual report released last week by the Centers for Medicare and Medicaid Services. On top of that $1.8 trillion, third-party programs, which are often government-funded, and public health programs accounted for another $600 billion in spendin
AbbVie to buy Cerevel in $8.7B bet on brain drugs
BioPharma Dive
DECEMBER 6, 2023
The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.
Don’t Get Distracted By AI, Instead Focus on Intellectual Property
PharmExec
DECEMBER 1, 2023
Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
Breaking: Pharmacy supervision consultation launches
The Pharmacist
DECEMBER 7, 2023
The Department of Health and Social Care (DHSC) has today launched its consultation into pharmacy supervision. It proposes to: enable pharmacists to authorise pharmacy technicians to carry out, or supervise others carrying out, the preparation, assembly, dispensing, sale and supply of medicines enable pharmacists to authorise any member of the pharmacy team to hand out […] The post Breaking: Pharmacy supervision consultation launches appeared first on The Pharmacist.
Why digital therapeutics (DTx) are effective and safe, but not being prescribed
pharmaphorum
DECEMBER 19, 2023
In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Joel Morse, CEO and co-founder of Curavit Clinical Research, and Andy Molnar, CEO of the Digital Therapeutics Alliance (DTA), for a discussion on why it is that digital therapeutics (DTx) are effective and safe, but not being prescribed.
Study confirms safety of new flow-diverting stent to treat brain aneurysms
Pharma Times
DECEMBER 13, 2023
In England, ruptured brain aneurysms occur in around one in 15,000 people every year - News - PharmaTimes
Kate Cox is one of hundreds in Texas denied abortions despite serious health risks, data show
STAT
DECEMBER 15, 2023
A Texas woman’s unsuccessful legal fight for an abortion on medical emergency grounds drew nationwide headlines in recent days, but her plight is hardly a rare occurrence amid vague and highly restrictive state laws in the post-Roe era. Kate Cox is likely one of hundreds, if not thousands, of Texans who’ve faced a similar struggle this year to get an abortion for medical reasons, according to a STAT review of studies and abortion data from other states.
Apellis eye drug likely to be rejected in Europe, company says
BioPharma Dive
DECEMBER 14, 2023
According to Apellis executives, reviewers in Europe are skeptical of the benefits of its geographic atrophy medicine, Syfovre, and appear poised to recommend against approval at a meeting next month.
Artificial Intelligence Changing the Landscape for Healthcare Social Media Marketing
PharmExec
DECEMBER 6, 2023
Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.
Let's personalize your content